New data reinforce the benefit of early preventative treatment with Hemlibra (emicizumab-kxwh) for babies with severe hemophilia A – Genentech/Roche
– Genentech, a member of the Roche Group announced that the primary analysis of the Phase III HAVEN 7 study reinforced the efficacy and safety of Hemlibra (emicizumab-kxwh)… read more.
